Evaluation of Paclitaxel as a Non-Cross-Resistant Agent in Cisplatin-Resistant Small Cell Lung Cancer (SCLC). ICRJ [Internet]. 2025 Sep. 25 [cited 2026 Feb. 6];1(1):2. Available from: https://icrj.meteorpub.com/1/article/view/7